CD44 in cancer
D Naor, S Nedvetzki, I Golan, L Melnik… - Critical reviews in …, 2002 - Taylor & Francis
CD44 is a multistructural and multifunctional cell surface molecule involved in cell
proliferation, cell differentiation, cell migration, angiogenesis, presentation of cytokines …
proliferation, cell differentiation, cell migration, angiogenesis, presentation of cytokines …
The state of CD44 activation in cancer progression and therapeutic targeting
Q Guo, C Yang, F Gao - The FEBS Journal, 2022 - Wiley Online Library
CD44, a non‐kinase transmembrane glycoprotein, is ubiquitously expressed on various
types of cells, especially cancer stem cells (CSCs), and has been implicated in cancer onset …
types of cells, especially cancer stem cells (CSCs), and has been implicated in cancer onset …
CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow
A Avigdor, P Goichberg, S Shivtiel, A Dar, A Peled… - Blood, 2004 - ashpublications.org
Trafficking of human CD34+ stem/progenitor cells (HSCs/HPCs) is regulated by
chemokines, cytokines, proteolytic enzymes, and adhesion molecules. We report that the …
chemokines, cytokines, proteolytic enzymes, and adhesion molecules. We report that the …
A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells
CJ Dimitroff, JY Lee, RC Fuhlbrigge… - Proceedings of the …, 2000 - National Acad Sciences
We previously have obtained operational evidence of a hematopoietic cell L-selectin ligand
expressed on normal human hematopoietic cells and on leukemic blasts. Using a technique …
expressed on normal human hematopoietic cells and on leukemic blasts. Using a technique …
Krüppel-like factor 5 mediates the transforming activity of oncogenic H-Ras
MO Nandan, HS Yoon, W Zhao, LA Ouko… - Oncogene, 2004 - nature.com
Previous studies indicate that Krüppel-like factor 5 (KLF5), also known as intestinal-enriched
Krüppel-like factor (IKLF), is a positive regulator of cell proliferation and gives rise to a …
Krüppel-like factor (IKLF), is a positive regulator of cell proliferation and gives rise to a …
A narrative review on CD44's role in glioblastoma invasion, proliferation, and tumor recurrence
A Inoue, T Ohnishi, M Nishikawa, Y Ohtsuka… - Cancers, 2023 - mdpi.com
Simple Summary As recurrence in glioblastoma is locally generated around the resection
cavity, surviving glioma stem-like cells may cause recurrence. Glioma stem-like cells …
cavity, surviving glioma stem-like cells may cause recurrence. Glioma stem-like cells …
A role for the cell adhesion molecule CD44 and sulfation in leukocyte–endothelial cell adhesion during an inflammatory response?
P Johnson, A Maiti, KL Brown, R Li - Biochemical pharmacology, 2000 - Elsevier
CD44 is a widely expressed cell adhesion molecule that has been implicated in a variety of
biological processes including lymphopoiesis, angiogenesis, wound healing, leukocyte …
biological processes including lymphopoiesis, angiogenesis, wound healing, leukocyte …
The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy‐induced toxicity
Chemotherapeutic agents are part of the standard treatment algorithms for many
malignancies; however, their application and dosage are limited by their toxic effects to …
malignancies; however, their application and dosage are limited by their toxic effects to …
The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells
Z Gadhoum, J Delaunay, E Maquarre… - Leukemia & …, 2004 - Taylor & Francis
Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing
number of immature myeloid cells arrested at various stages of granulocytic and monocytic …
number of immature myeloid cells arrested at various stages of granulocytic and monocytic …
Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy
K Kemp, R Morse, S Wexler, C Cox, E Mallam… - Annals of …, 2010 - Springer
Hematopoietic recovery after high-dose chemotherapy (HDC) in the treatment of
hematological diseases may be slow and/or incomplete. This is generally attributed to …
hematological diseases may be slow and/or incomplete. This is generally attributed to …